SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company that entered the public markets in 2021 through a business combination with Big Rock Partners Acquisition Corp., a blank-check company sponsored by Big Rock Partners. Headquartered in Rapid City, South Dakota, SAB develops fully human polyclonal antibodies using genetically engineered human immunoglobulin cattle, with programs targeting infectious diseases and other therapeutic areas. The company filed an 8-K with the SEC on June 18, 2026, under accession number 0001193125-26-275976, and has maintained its Nasdaq listing since completing the de-SPAC transaction. To access SAB Biotherapeutics' full filing history, deal timeline, and real-time SPAC analytics, sign up for complete data on SpacDesk.